These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 20660181

  • 1. Alterations in the immunogenic properties of soluble trimeric human immunodeficiency virus type 1 envelope proteins induced by deletion or heterologous substitutions of the V1 loop.
    Ching L, Stamatatos L.
    J Virol; 2010 Oct; 84(19):9932-46. PubMed ID: 20660181
    [Abstract] [Full Text] [Related]

  • 2. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region.
    Srivastava IK, VanDorsten K, Vojtech L, Barnett SW, Stamatatos L.
    J Virol; 2003 Feb; 77(4):2310-20. PubMed ID: 12551968
    [Abstract] [Full Text] [Related]

  • 3. The first hypervariable region of the gp120 Env glycoprotein defines the neutralizing susceptibility of heterologous human immunodeficiency virus type 1 isolates to neutralizing antibodies elicited by the SF162gp140 immunogen.
    Ching LK, Vlachogiannis G, Bosch KA, Stamatatos L.
    J Virol; 2008 Jan; 82(2):949-56. PubMed ID: 18003732
    [Abstract] [Full Text] [Related]

  • 4. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.
    Li Y, Svehla K, Mathy NL, Voss G, Mascola JR, Wyatt R.
    J Virol; 2006 Feb; 80(3):1414-26. PubMed ID: 16415019
    [Abstract] [Full Text] [Related]

  • 5. Antigenicity and immunogenicity of HIV-1 gp140 with different combinations of glycan mutation and V1/V2 region or V3 crown deletion.
    Fu M, Hu K, Hu H, Ni F, Du T, Shattock RJ, Hu Q.
    Vaccine; 2019 Dec 03; 37(51):7501-7508. PubMed ID: 31564450
    [Abstract] [Full Text] [Related]

  • 6. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT, Chamcha V, Kesavardhana S, Shen X, Beaumont D, Das R, Wyatt LS, LaBranche CC, Stanfield-Oakley S, Ferrari G, Montefiori DC, Moss B, Tomaras GD, Varadarajan R, Amara RR.
    J Virol; 2018 Mar 01; 92(5):. PubMed ID: 29237847
    [Abstract] [Full Text] [Related]

  • 7. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.
    Derby NR, Kraft Z, Kan E, Crooks ET, Barnett SW, Srivastava IK, Binley JM, Stamatatos L.
    J Virol; 2006 Sep 01; 80(17):8745-62. PubMed ID: 16912322
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S, Kumar R, Deshpande S, Samal S, Shrivastava T, Boliar S, Bansal M, Chaudhary NK, Srikrishnan AK, Murugavel KG, Solomon S, Simek M, Koff WC, Goyal R, Chakrabarti BK, Bhattacharya J.
    J Virol; 2016 Jan 13; 90(7):3446-57. PubMed ID: 26763999
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Rationally designed carbohydrate-occluded epitopes elicit HIV-1 Env-specific antibodies.
    Zhu C, Dukhovlinova E, Council O, Ping L, Faison EM, Prabhu SS, Potter EL, Upton SL, Yin G, Fay JM, Kincer LP, Spielvogel E, Campbell SL, Benhabbour SR, Ke H, Swanstrom R, Dokholyan NV.
    Nat Commun; 2019 Feb 27; 10(1):948. PubMed ID: 30814513
    [Abstract] [Full Text] [Related]

  • 12. Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development.
    Malherbe DC, Wibmer CK, Nonyane M, Reed J, Sather DN, Spencer DA, Schuman JT, Guo B, Pandey S, Robins H, Park B, Fuller DH, Sacha JB, Moore PL, Hessell AJ, Haigwood NL.
    Front Immunol; 2020 Feb 27; 11():984. PubMed ID: 32582155
    [Abstract] [Full Text] [Related]

  • 13. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.
    McGuire AT, Glenn JA, Lippy A, Stamatatos L.
    J Virol; 2014 Mar 27; 88(5):2645-57. PubMed ID: 24352455
    [Abstract] [Full Text] [Related]

  • 14. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM, McKeating JA, de Souza JB, Roitt IM, Delves PJ, Lund T.
    Virology; 1998 Nov 10; 251(1):59-70. PubMed ID: 9813203
    [Abstract] [Full Text] [Related]

  • 15. A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.
    Beddows S, Franti M, Dey AK, Kirschner M, Iyer SP, Fisch DC, Ketas T, Yuste E, Desrosiers RC, Klasse PJ, Maddon PJ, Olson WC, Moore JP.
    Virology; 2007 Apr 10; 360(2):329-40. PubMed ID: 17126869
    [Abstract] [Full Text] [Related]

  • 16. Immunogenic Display of Purified Chemically Cross-Linked HIV-1 Spikes.
    Leaman DP, Lee JH, Ward AB, Zwick MB.
    J Virol; 2015 Jul 10; 89(13):6725-45. PubMed ID: 25878116
    [Abstract] [Full Text] [Related]

  • 17. Structure-Based Design of a Soluble Prefusion-Closed HIV-1 Env Trimer with Reduced CD4 Affinity and Improved Immunogenicity.
    Chuang GY, Geng H, Pancera M, Xu K, Cheng C, Acharya P, Chambers M, Druz A, Tsybovsky Y, Wanninger TG, Yang Y, Doria-Rose NA, Georgiev IS, Gorman J, Joyce MG, O'Dell S, Zhou T, McDermott AB, Mascola JR, Kwong PD.
    J Virol; 2017 May 15; 91(10):. PubMed ID: 28275193
    [Abstract] [Full Text] [Related]

  • 18. Engineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.
    Sellhorn G, Kraft Z, Caldwell Z, Ellingson K, Mineart C, Seaman MS, Montefiori DC, Lagerquist E, Stamatatos L.
    J Virol; 2012 Jan 15; 86(1):128-42. PubMed ID: 22031951
    [Abstract] [Full Text] [Related]

  • 19. Envelope proteins of two HIV-1 clades induced different epitope-specific antibody response.
    Shrivastava T, Samal S, Tyagi AK, Goswami S, Kumar N, Ozorowski G, Ward AB, Chakrabarti BK.
    Vaccine; 2018 Mar 14; 36(12):1627-1636. PubMed ID: 29429810
    [Abstract] [Full Text] [Related]

  • 20. Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution.
    Bontjer I, Land A, Eggink D, Verkade E, Tuin K, Baldwin C, Pollakis G, Paxton WA, Braakman I, Berkhout B, Sanders RW.
    J Virol; 2009 Jan 14; 83(1):368-83. PubMed ID: 18922866
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.